Rituximab can Decrease Proteinuria in Refractory Lupus Nephritis

Chang-Hee Suh^{1

2}

Affiliations

¹ Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
² Department of Molecular Science and Technology, Ajou University, Suwon, Korea.

Editorial

Chang-Hee Suh. J Rheum Dis. 2022.

. 2022 Apr 1;29(2):59-60.

doi: 10.4078/jrd.2022.29.2.59.

Chang-Hee Suh^{1

2}

¹ Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea.
² Department of Molecular Science and Technology, Ajou University, Suwon, Korea.

No abstract available

Conflict of interest statement

CONFLICT OF INTEREST No potential conflict of interest relevant to this article was reported.

1. Mejia-Vilet JM, Malvar A, Arazi A, Rovin BH. The lupus nephritis management renaissance. Kidney Int. 2022;101:242–55. doi: 10.1016/j.kint.2021.09.012. - DOI - PubMed
1. Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med. 2020;383:1117–28. doi: 10.1056/NEJMoa2001180. - DOI - PubMed
1. Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, et al. Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2021;397:2070–80. doi: 10.1016/S0140-6736(21)00578-X. - DOI - PubMed
1. Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant. 2013;28:106–11. doi: 10.1093/ndt/gfs285. - DOI - PubMed
1. Cervera R, Mosca M, Ríos-Garcés R, Espinosa G, Trujillo H, Bada T, et al. Treatment for refractory lupus nephritis: rituximab vs triple target therapy. Autoimmun Rev. 2019;18:102406. doi: 10.1016/j.autrev.2019.102406. - DOI - PubMed